
News|Articles|September 13, 2023
EMPOWERing the Next Generation
Author(s)Erica Koenig, PhD
An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.
Advertisement
CONFERENCE REPORTER
Erica Koenig, PhD, gives an overview of Cerevel Therapeutics and discusses EMPOWER, a phase 2 clinical trial evaluating emraclidine for the treatment of schizophrenia. Koenig presented this research in a poster presentation at Psych Congress 2023.
Dr Koenig is program lead of emraclidine and senior director of global clinical development at Cerevel Therapeutics.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Competence and Compassion in the Reiner Family Tragedy
2
Latest Alzheimer Disease Data: Reports from CTAD 2025
3
Programs for ST-905 and ST-905 for Schizophrenia and Depression Launched by Syremis Therapeutics
4
Dronabinol for Agitation in Autism Spectrum Disorder: Research From the National Update on Behavioral Emergencies Conference
5

















